Cover Image
Market Research Report

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2018

Published by Global Markets Direct Product code 358687
Published Content info 83 Pages
Delivery time: 1-2 business days
Price
Back to Top
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2018
Published: September 11, 2018 Content info: 83 Pages
Description

Summary:

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 20 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The latest report Growth Hormone Secretagogue Receptor - Pipeline Review, H2 2018, outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland.

The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 1, 11 and 1 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Metabolic Disorders, Central Nervous System, Toxicology, Cardiovascular, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hormonal Disorders, Infectious Disease and Musculoskeletal Disorders which include indications Cancer Anorexia-Cachexia Syndrome, Obesity, Prader-Willi Syndrome (PWS), Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Cachexia, Chemotherapy Effects, Chronic Kidney Disease (Chronic Renal Failure), Diabetes, Diabetic Gastroparesis, Fatigue, Growth Hormone Deficiency, Ischemia, Sepsis and Traumatic Brain Injury.

Furthermore, this report also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC1655TDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Overview
    • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
    • Aeterna Zentaris Inc
    • Allergan Plc
    • AstraZeneca Plc
    • Daiichi Sankyo Co Ltd
    • Millendo Therapeutics Inc
    • Oxeia Biopharmaceuticals Inc
    • Pfizer Inc
    • RaQualia Pharma Inc
    • Zeria Pharmaceutical Co Ltd
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles
    • anamorelin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZ-12861903 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXT-400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EXT-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-03 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HM-04 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ibutamoren mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • livoletide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • macimorelin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OXE-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-05190457 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relamorelin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RQ-00433412 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Ghrelin Receptor for Obesity - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize GHSR for Cachexia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulimorelin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Z-505 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Products
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products
  • Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 28, 2018: URI drug study produces 'promising therapy' for alcohol abuse
      • Mar 05, 2018: Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit
      • Mar 05, 2018: Lyric Completes Enrollment in Phase 2 PROMOTE Study of LP101 (Ulimorelin) in Enteral Feeding Intolerance
      • Jan 23, 2018: Lyric Pharmaceuticals Presents Data at ASPEN Conference on the Incidence of Enteral Feeding Intolerance in the ICU
      • Jan 17, 2018: Lyric Pharma Granted FDA Fast Track Designation for Lead Product Ulimorelin for Enteral Feeding Intolerance
      • Dec 20, 2017: Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency
      • Nov 27, 2017: Aeterna Zentaris Marketing Authorization Application for Macrilen (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency
      • Sep 15, 2017: Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
      • Sep 06, 2017: Oxeia Biopharmaceuticals Announces Appointment Of Dr. Michael Wyand As Chief Executive Officer
      • Aug 23, 2017: Richard Sherman, NFL All-Pro, Joins Oxeia Biopharmaceuticals Advisory Board
      • Jul 18, 2017: NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
      • Jun 30, 2017: Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults
      • Jun 19, 2017: Ammonett Pharma Granted Orphan Drug Designation From the U.S. FDA for Ibutamoren Mesylate (MK-0677) for Treatment of Growth Hormone Deficiency
      • May 25, 2017: Ammonett Pharma Receives Notice of Allowance of U.S. Patent for Oratrope Related to Detecting and Treating Growth Hormone Deficiency
      • May 23, 2017: Ammonett Pharma Receives Positive Opinion from European Orphan Medicinal Products Committee for MK-0677 for Treatment of Pediatric Growth Hormone Deficiency
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Indication, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Companies, H2 2018 (Contd..1), H2 2018
  • Number of Products under Investigation by Universities/Institutes, H2 2018
  • Products under Investigation by Universities/Institutes, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Stage and Route of Administration, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Pipeline by Aeterna Zentaris Inc, H2 2018
  • Pipeline by Allergan Plc, H2 2018
  • Pipeline by AstraZeneca Plc, H2 2018
  • Pipeline by Daiichi Sankyo Co Ltd, H2 2018
  • Pipeline by Millendo Therapeutics Inc, H2 2018
  • Pipeline by Oxeia Biopharmaceuticals Inc, H2 2018
  • Pipeline by Pfizer Inc, H2 2018
  • Pipeline by RaQualia Pharma Inc, H2 2018
  • Pipeline by Zeria Pharmaceutical Co Ltd, H2 2018
  • Dormant Products, H2 2018
  • Dormant Products, H2 2018 (Contd..1), H2 2018
  • Dormant Products, H2 2018 (Contd..2), H2 2018
  • Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development by Stage of Development, H2 2018
  • Number of Products under Development by Therapy Areas, H2 2018
  • Number of Products under Development by Top 10 Indications, H2 2018
  • Number of Products by Mechanism of Actions, H2 2018
  • Number of Products by Stage and Mechanism of Actions, H2 2018
  • Number of Products by Routes of Administration, H2 2018
  • Number of Products by Stage and Routes of Administration, H2 2018
  • Number of Products by Molecule Types, H2 2018
  • Number of Products by Stage and Molecule Types, H2 2018
Back to Top